Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
Total Valuation
10x Genomics has a market cap or net worth of $1.18B. The enterprise value is ―.
Market Cap$1.18B
Enterprise Value―
Share Statistics
10x Genomics has 111,092,770 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding111,092,770
Owned by Insiders2.65%
Owned by Institutions36.54%
Financial Efficiency
10x Genomics’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -24.68%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-24.68%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee467.68K
Profits Per Employee-139.84K
Employee Count1,306
Asset Turnover0.66
Inventory Turnover2.36
Valuation Ratios
The current PE Ratio of 10x Genomics is -9.47. 10x Genomics’s PEG ratio is ―.
PE Ratio-9.47
PS Ratio0.00
PB Ratio1.48
Price to Fair Value2.44
Price to FCF-158.67
Price to Operating Cash Flow157.79
PEG Ratio―
Income Statement
In the last 12 months, 10x Genomics had revenue of 610.78M and earned -182.63M in profits. Earnings per share was -1.52.
Revenue610.78M
Gross Profit414.48M
Operating Income-194.56M
Pretax Income-177.70M
Net Income-182.63M
EBITDA-133.99M
Earnings Per Share (EPS)-1.52
Cash Flow
In the last 12 months, operating cash flow was 6.66M and capital expenditures -13.39M, giving a free cash flow of -6.73M billion.
Operating Cash Flow6.66M
Free Cash Flow-6.73M
Free Cash Flow per Share-0.06
Dividends & Yields
10x Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.81
52-Week Price Change-57.53%
50-Day Moving Average8.57
200-Day Moving Average14.09
Relative Strength Index (RSI)55.72
Average Volume (3m)3.56M
Important Dates
10x Genomics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
10x Genomics as a current ratio of 4.97, with Debt / Equity ratio of 11.63%
Current Ratio4.97
Quick Ratio4.26
Debt to Market Cap0.05
Net Debt to EBITDA1.95
Interest Coverage Ratio-48.64K
Taxes
In the past 12 months, 10x Genomics has paid 4.93M in taxes.
Income Tax4.93M
Effective Tax Rate-0.03
Enterprise Valuation
10x Genomics EV to EBITDA ratio is -10.96, with an EV/FCF ratio of -256.28.
EV to Sales2.40
EV to EBITDA-10.96
EV to Free Cash Flow-256.28
EV to Operating Cash Flow220.32
Balance Sheet
10x Genomics has $393.40M in cash and marketable securities with $82.61M in debt, giving a net cash position of -$310.79M billion.
Cash & Marketable Securities$393.40M
Total Debt$82.61M
Net Cash-$310.79M
Net Cash Per Share-$2.80
Tangible Book Value Per Share$5.73
Margins
Gross margin is 68.73%, with operating margin of -31.85%, and net profit margin of -29.90%.
Gross Margin68.73%
Operating Margin-31.85%
Pretax Margin-29.09%
Net Profit Margin-29.90%
EBITDA Margin-21.94%
EBIT Margin-29.09%
Analyst Forecast
The average price target for 10x Genomics is $13.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$13.00
Price Target Upside38.00% Upside
Analyst ConsensusModerate Buy
Analyst Count10
Revenue Growth Forecast-0.13%
EPS Growth Forecast42.17%